Looks as bad as a deal as allowing CSM get away with the sabotage ( I like those Great Point Capital ties that paid back CEO of CSM Clinical Supplies Management Gerald Finken in global expansion )
Roth Capital Partners also to blame as they gave the Fairness Opinion...see that letter yet ?
Maybe Roth based their opinion report on John Springs Stafford thoughts of the IP ...oh wait, Stafford would have given it away for free
Now comes some that believe the current Avid BOD is the "best" case...my best case would be get the IP back based on failures of Oncologie in jumping on NSCLC and Breast cancer ....oh but wait, Merck sandbox friends don't like that lol
I still have reservations for the IP being slow played but heck, CDMO soon at $40+ a share with capacity full and expansion coming ...it's the trade off that seemed to have been agreed upon
Now we will likely hear from opinions saying we will never see $40 from those STILL hanging around for some reason, maybe because IIS at record highs and some not settling for $20 $30 or $40
The Big Pharma Mafia cartel would have been shaken and rocked ...IF Bavi was allowed into FDA approval back in 2012 which would have spoiled Opdivo and Ketruda etc revenues in the short term
In the long term, they can't pay off everyone
Market Data 
Markets 
AI
